Clarity Pharmaceuticals Launches Phase II SECuRE Trial in Prostate Cancer

Australian radiopharmaceutical firm Clarity Pharmaceuticals announced its first patient dosing in the Phase II SECuRE trial, using 67Cu-SAR-bisPSMA to target metastatic castration-resistant prostate cancer. The expanded trial, now featuring up to 6 therapy cycles and a new combination arm with enzalutamide, leverages an improved product formulation for stability and large-scale manufacture. These advances may advance next-generation PSMA-targeted theranostics for personalized oncology care.

Immunic Completes Enrollment in Dual Phase 3 MS Trials

Immunic finished enrolling patients in both ENSURE Phase 3 clinical trials for its oral therapy vidofludimus calcium in relapsing multiple sclerosis. Expected top-line data at year’s end will crystallize its market position as a potential competitor to current MS therapies, adding to the industry’s late-stage neuroimmunology pipeline strength.

Big Money Moves: Kelun-Biotech Raises $250M to Advance ADC Pipeline

Kelun-Biotech, a leading China-based biopharma, closed a $250 million funding placement to ramp up its antibody-drug conjugate (ADC) and biopharmaceutical development. The fundraising highlights robust investor confidence in targeted oncology drugs, sustaining the global race for new bioconjugate platforms.

Industry Events and Partnerships Highlight Collaboration

The 2nd Annual Structure-Based Drug Design Summit in Boston brought together global leaders in computational drug discovery, structure-guided design, and novel protein therapeutics development. Meanwhile, new licensing agreements, such as Sumitomo Pharma partnering with Knight Therapeutics for Canadian commercialization, point to ongoing globalization and cross-border collaboration.

Research, Funding, and Strategic Trends

Strategic acquisitions, new academic-industry partnerships, and sustained public market funding reflect a biotech sector adapting to new regulatory and market realities. Companies are focusing investments into later-stage and precision-medicine assets while advancing modalities like radiopharmaceuticals, gene editing, and immunomodulators.